Financial Performance - The company's operating revenue for Q1 2022 was CNY 285,492,762.95, representing a year-on-year increase of 12.50%[5] - Net profit attributable to shareholders was CNY 70,676,062.51, reflecting a significant increase of 76.94% compared to the same period last year[5] - Basic and diluted earnings per share were both CNY 0.21, marking a growth of 75.00% year-on-year[5] - Total revenue for Q1 2022 reached ¥285,492,762.95, an increase of 12.5% compared to ¥253,770,979.45 in Q1 2021[18] - Net profit for Q1 2022 was ¥75,059,325.56, compared to ¥39,783,177.10 in Q1 2021, representing an increase of 88.5%[19] - Total revenue for Q1 2022 reached CNY 72,996,128.67, a significant increase from CNY 36,806,172.54 in Q1 2021, representing a growth of approximately 98.2%[20] - The net profit for Q1 2022 reached CNY 61,949,170.22, a significant recovery from a net loss of CNY 4,414,385.71 in Q1 2021[30] Cash Flow and Liquidity - The net cash flow from operating activities reached CNY 110,443,571.72, showing a remarkable increase of 355.81%[5] - Cash and cash equivalents at the end of Q1 2022 totaled CNY 306,438,419.83, compared to CNY 354,285,347.72 at the end of Q1 2021, showing a decrease of approximately 13.5%[24] - The company's cash inflow from financing activities in Q1 2022 was CNY 101,573,975.50, down from CNY 372,734,302.00 in Q1 2021, indicating a decline of approximately 72.8%[24] - The net cash flow from investing activities for Q1 2022 was -CNY 78,419,068.25, compared to -CNY 84,258,258.98 in Q1 2021, showing an improvement of about 6.5%[24] - The company's cash flow from operating activities showed a net outflow of CNY 21,275,893.11 in Q1 2022, compared to a smaller outflow of CNY 2,144,245.49 in Q1 2021[32] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,489,353,794.67, up 2.65% from the end of the previous year[6] - Total assets as of March 31, 2022, amounted to ¥2,489,353,794.67, compared to ¥2,425,061,985.01 at the end of 2021, indicating a growth of 2.6%[15] - Total liabilities decreased slightly to ¥1,041,789,422.78 from ¥1,050,493,741.79, a reduction of 0.5%[16] - The total liabilities as of Q1 2022 amounted to CNY 407,785,840.84, slightly up from CNY 403,438,134.47 in the previous year[29] - The company’s total liabilities as of March 31, 2022, were CNY 1,382,405,973.81, reflecting a stable financial position compared to previous periods[26] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 39,665[10] - The largest shareholder, Shuangge Group Co., Ltd., held 29.40% of the shares, totaling 100,166,800 shares[11] Research and Development - Research and development expenses for Q1 2022 were ¥7,845,210.89, up from ¥6,619,541.57 in Q1 2021, an increase of 18.5%[19] - Research and development expenses were CNY 2,045,646.41 in Q1 2022, a decrease from CNY 2,381,238.43 in Q1 2021[29] Other Income and Expenses - Non-recurring gains and losses amounted to CNY 9,157,173.55, with significant contributions from government subsidies and other income[7] - The company reported an investment income of ¥9,849,463.05 in Q1 2022, compared to a loss of ¥680,808.75 in Q1 2021[19] - The company achieved an investment income of CNY 72,953,628.30 in Q1 2022, a substantial increase from CNY 674,523.59 in Q1 2021[29] - The company reported a decrease in financial expenses to CNY 3,484,767.84 in Q1 2022, down from CNY 5,574,186.01 in Q1 2021[29]
济民医疗(603222) - 2022 Q1 - 季度财报